Sonnet biotherapeutics announces preclinical data supporting its bispecific interleukin candidates at the american association for cancer research (aacr) 2022 annual meeting

Princeton, nj / accesswire / april 8, 2022 / sonnet biotherapeutics holdings, inc., (nasdaq:sonn) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from preclinical studies of the company's proprietary fully-human albumin binding candidates, son-1010, son-1210, and son-1410, will be presented in a poster session at the american association for cancer research (aacr) annual meeting 2022, april 8-13, in new orleans, louisiana. "we are excited about these data that support tumor growth reduction following administration of both son-1210 and son-1410 in a b16-f10 melanoma model in mice," said john cini, ph.d.
SONN Ratings Summary
SONN Quant Ranking